<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05006235</url>
  </required_header>
  <id_info>
    <org_study_id>MansouraUCH0321</org_study_id>
    <nct_id>NCT05006235</nct_id>
  </id_info>
  <brief_title>Inhaled Beta-2 Agonist Versus Epinephrine For Treatment of Transient Tachypnea of Newborn (TTN)</brief_title>
  <official_title>Inhaled Beta-2 Agonist Versus Epinephrine For Treatment of Transient Tachypnea of Newborn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmed Noaman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University Children Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inhaled Beta-2 Agonist Versus Epinephrine For Treatment of Transient Tachypnea of Newborn:&#xD;
      Randomized controlled trial to assess:&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double-blind randomized controlled trial. It had been conducted at the&#xD;
      Neonatal Intensive Care Unit (NICU) of Mansoura University Children's Hospital, Egypt Written&#xD;
      informed consent had been taken from all parents whose infants were recruited in the study.&#xD;
      The ethics committee of the faculty of medicine has approved the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2014</start_date>
  <completion_date type="Actual">December 31, 2015</completion_date>
  <primary_completion_date type="Actual">December 31, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of oxygen support &amp; O2 concentration until Downes' score less than 4</measure>
    <time_frame>through study completion, about 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay until Downes' score less than 4</measure>
    <time_frame>through study completion, about 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of respiratory support (oxygen delivery and oxygen concentration)</measure>
    <time_frame>within 12 hours after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of intervention on blood sugar (mg/dl)</measure>
    <time_frame>within 12 hours after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Transient Tachypnea of the Newborn</condition>
  <arm_group>
    <arm_group_label>Salbutamol Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>included babies who had received nebulized B2 agonist salbutamol (0.15 mg/kg) + 4ml normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epinephrine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>included babies who had received nebulized epinephrine (0, 05 ml/Kg) + 4ml normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>include babies who had received nebulized 0.9% saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine Inhalation Solution</intervention_name>
    <arm_group_label>Epinephrine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <arm_group_label>Salbutamol Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Inhalants</intervention_name>
    <arm_group_label>Saline Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  babies with 35 weeks of gestation or more in the first 6 hours of life diagnosed with&#xD;
             TTN according to the criteria of which are:&#xD;
&#xD;
               -  Tachypnea (respiratory rate exceeding 60 breaths/ min) within 6 hours after birth&#xD;
&#xD;
               -  Persistence of tachypnea for at least 12 hours&#xD;
&#xD;
               -  Mild cyanosis, nasal flaring, or retractions.&#xD;
&#xD;
               -  Chest radiograph indicating at least one of the following:&#xD;
&#xD;
          -  Prominent central vascular markings&#xD;
&#xD;
          -  Widened interlobar fissures&#xD;
&#xD;
          -  Symmetrical perihilar congestion&#xD;
&#xD;
          -  Hyperaeration is evidenced by flattening and depression of the diaphragmatic domes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Newborn infants with gestational age &lt; 35 weeks&#xD;
&#xD;
          -  Meconium aspiration&#xD;
&#xD;
          -  Respiratory distress syndrome&#xD;
&#xD;
          -  Pneumonia&#xD;
&#xD;
          -  Congenital heart diseases including persistent pulmonary hypertension of the neworn&#xD;
             (PPHN)&#xD;
&#xD;
          -  Sepsis or suspected sepsis&#xD;
&#xD;
          -  Polycythemia&#xD;
&#xD;
          -  Newborn infants with congenital malformations and chromosomal anomalies&#xD;
&#xD;
          -  Newborn infants with ventilatory support.&#xD;
&#xD;
          -  Newborn infants with arrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Bertrand P, Araníbar H, Castro E, Sánchez I. Efficacy of nebulized epinephrine versus salbutamol in hospitalized infants with bronchiolitis. Pediatr Pulmonol. 2001 Apr;31(4):284-8.</citation>
    <PMID>11288210</PMID>
  </reference>
  <reference>
    <citation>Clark RH. The epidemiology of respiratory failure in neonates born at an estimated gestational age of 34 weeks or more. J Perinatol. 2005 Apr;25(4):251-7.</citation>
    <PMID>15605071</PMID>
  </reference>
  <reference>
    <citation>Rawlings JS, Smith FR. Transient tachypnea of the newborn. An analysis of neonatal and obstetric risk factors. Am J Dis Child. 1984 Sep;138(9):869-71.</citation>
    <PMID>6540983</PMID>
  </reference>
  <reference>
    <citation>Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, Saugstad OD, Simeoni U, Speer CP, Vento M, Halliday HL; European Association of Perinatal Medicine. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants--2013 update. Neonatology. 2013;103(4):353-68. doi: 10.1159/000349928. Epub 2013 May 31.</citation>
    <PMID>23736015</PMID>
  </reference>
  <reference>
    <citation>Vollsæter M, Røksund OD, Eide GE, Markestad T, Halvorsen T. Lung function after preterm birth: development from mid-childhood to adulthood. Thorax. 2013 Aug;68(8):767-76. doi: 10.1136/thoraxjnl-2012-202980. Epub 2013 Jun 7.</citation>
    <PMID>23749815</PMID>
  </reference>
  <reference>
    <citation>Yurdakök M. Transient tachypnea of the newborn: what is new? J Matern Fetal Neonatal Med. 2010 Oct;23 Suppl 3:24-6. doi: 10.3109/14767058.2010.507971. Review.</citation>
    <PMID>20807157</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>August 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 7, 2021</last_update_submitted>
  <last_update_submitted_qc>August 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University Children Hospital</investigator_affiliation>
    <investigator_full_name>Ahmed Noaman</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <keyword>Transient Tachypnea of the Newborn (TTN)</keyword>
  <keyword>epinephrine</keyword>
  <keyword>salbutamol</keyword>
  <keyword>respiratory distress</keyword>
  <keyword>newborn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachypnea</mesh_term>
    <mesh_term>Transient Tachypnea of the Newborn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

